Centro de Investigación del Cáncer

TP53 mutations and IGHV in naïve chronic lymphocytic leukemia: retrospective analysis of data from a Spanish collaborative network

Abstract This retrospective study involving 225 centers assessed TP53 and IGHV molecular status and stereotyped BcR IG subsets in a large cohort of patients with CLL in Spain using data from the RED53 project. Three analytical reference centers determined the mutational status of...

Genomic and clinical landscape of RAS mutations in acute myeloid leukemia

RAS mutations are recurrent in acute myeloid leukemia (AML); yet, their genomic and clinical landscape remain poorly characterized. We analyzed centralized molecular profiling data in 8,553 patients with newly diagnosed AML. Of these, 1,775 (21%) harbored RAS mutations: NRAS in 1...

Early measurement of ST2 and REG3α has a prognostic impact in haploidentical transplantation with post-transplant cyclophosphamide

Research on predictive biomarkers in haploidentical SCT (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) remains limited, particularly regarding the critical first week post-infusion. We prospectively evaluated serum ST2, REG3α, and the MAGIC algorithm pre-conditioning a...

Antibody-drug conjugate engineering: from design to efficacy and safety

Antibody–drug conjugates (ADCs) represent a rapidly expanding class of targeted cancer therapeutics that combine the high selectivity of monoclonal antibodies with the potent cytotoxic activity of small-molecule drugs. Their clinical success relies on the simultaneous optimizatio...

Paclitaxel induces NM2 ‐dependent cellular contraction through GEF ‐ H1 dissociation from microtubules and RhoA / ROCK activation in cancer cells

In this study, we have investigated the crosstalk between microtubule dynamics and actomyosin contractility in cancer cells treated with taxanes, which are chemotherapeutic agents used to treat solid tumors. We found that paclitaxel (PTXL) induced cell contraction through a mecha...

Whole-genome sequencing of Reed-Sternberg cells identifies outcome determinants in Hodgkin lymphoma

Abstract Classical Hodgkin lymphoma (cHL) is a B-cell-derived malignancy characterized by rare Hodgkin and Reed–Sternberg (HRS) cells within an extensive inflammatory microenvironment. Although most patients achieve durable remission with first-line therapy, a subset relapse or e...

Machine learning provides individualized prediction of outcomes after first complete remission without allo‐HSCT consolidation in adult acute myeloid leukemia—A HARMONY study

Abstract Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a curative treatment option for a significant proportion of patients with acute myeloid leukemia (AML), and it is generally recommended when the relapse risk without allo‐HSCT outweighs the estimated non‐r...

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study

Plain Language SummaryWhat is this summary about?This summary describes how well talquetamab worked and its safety at a median (midpoint) of 17–26 months follow-up from the MonumenTAL-1 study, which tested talquetamab treatment for a type of cancer called relapsed/refractory mult...

A RAC1 SUMOylation switch governs breast cancer metastasis

Despite the major advances in breast cancer management over the past few decades, metastatic breast cancer continues to be a major concern and the main cause of mortality associated with this disease. The Rho GTPase RAC1 has been implicated in breast cancer aggressiveness, yet th...